ALDH2 Modulators Reduce Aldehyde Toxicity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for conditions associated with mitochondrial aldehyde dehydrogenase-2 (ALDH2) deficiencies, such as ischemic stress, alcoholism, and cancer, lack effective modulators to manage aldehyde levels and oxidative stress effectively.

Innovation Solution

Development of specific compounds that act as modulators, agonists, or antagonists of ALDH2 to regulate its activity, reducing aldehyde levels and treating associated disorders by administering these compounds in pharmaceutical compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for ALDH2 deficiencies, then general symptom management is provided, but effective modulation of aldehyde levels and oxidative stress is not achieved

Engineering Contradiction:
Improveeffectiveness of treatmentVSAvoidability to manage aldehyde levels
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by developing compounds that specifically modulate ALDH2 enzyme activity. The chemical structures (formulas I-IV) represent modified molecular parameters designed to interact with and regulate ALDH2, thereby changing the physiological parameters of aldehyde metabolism and oxidative stress levels to achieve therapeutic effects.

Inventive Principle:
Principle #35Parameter changes

2Object-affected harmful factors

If ALDH2 activity is not modulated, then natural aldehyde metabolism occurs, but toxic aldehyde levels and oxidative stress persist

Engineering Contradiction:
Improvealdehyde toxicityVSAvoidtherapeutic benefit
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful accumulation of aldehydes into a beneficial therapeutic outcome by using ALDH2 modulators to enhance the enzyme's activity. The compounds transform the toxic metabolic pathway into a protective mechanism, where increased ALDH2 activity converts harmful aldehydes into less toxic products, thereby converting harm into benefit.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Adaptability or versatility

If specific ALDH2 modulators are developed, then effective treatment of alcohol-related disorders and cancer is achieved, but complexity of pharmaceutical development increases

Engineering Contradiction:
Improvetreatment coverage for multiple disordersVSAvoidpharmaceutical composition complexity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies universality by designing ALDH2 modulators with broad therapeutic applications. The same compound class (formulas I-IV) can treat multiple disorders including alcohol-related conditions, cancer, and other diseases associated with ALDH2 dysfunction, achieving multi-functionality through a unified mechanistic approach.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively reduce aldehyde levels, treat alcohol-related disorders, and prevent conditions like cancer by modulating ALDH2 activity, providing therapeutic benefits for conditions involving oxidative stress and aldehyde toxicity.

Implementation Method 1

Mitochondrial aldehyde dehydrogenase-2 (ALDH2) is encoded in the nuclear genome and is transported into mitochondria. ALDH2 is a tetrameric protein composed of four identical subunits... Each subunit is composed of three main domains: the catalytic domain, the coenzyme or NAD+

Methodology Applied
Scientific EffectEnzyme catalysis: Enzyme

Data Source

PatentEP2970124B1Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
Publication Date: 2019.05.22 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
  • EP2970124B1 patent drawingFigure 1
  • EP2970124B1 patent drawingFigure 2
  • EP2970124B1 patent drawingFigure 3

AI summary

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.